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Background: Platelet aggregation is one of the most important factors in the development of thrombotic
disorders which plays a central role in thrombosis (clot formation). Prophylaxis and treatment of arterial thrombosis
are achieved using anti-platelet drugs. In this study, a series of novel substituted indole carbohydrazide was
synthesized and evaluated for anti-platelet aggregation activity induced by adenosine diphosphate (ADP), arachidonic
acid (AA) and collagen.
Methods: Our synthetic route started from methyl 1H-indole-3-carboxylate (1) and ethyl 1H-indole-2-carboxylate
(4) which were reacted with hydrazine monohydrate 99%. The aldol condensation of the later compound with
aromatic aldehydes led to the formation of the title compounds. Sixteen indole acylhydrazone derivatives, 3d-m
and 6d-i were tested for anti-platelet aggregation activity induced by adenosine diphosphate (ADP), arachidonic
acid (AA) and collagen.
Results: Among the synthesized compounds, 6g and 6h with 100% inhibition, proved to be the most potent
derivatives of the 2-substituted indole on platelet aggregation induced by AA and collagen, respectively. In
3-substituted indole 3m with 100% inhibition and 3f and 3i caused 97% inhibition on platelet aggregation
induced by collagen and AA, respectively.
Conclusion: In this study, compounds 6g, 6h, 3m, 3f and 3i showed better inhibition on platelet aggregation
induced by AA and collagen among the title compounds. Quantitative structure–activity relationship (QSAR)
analysis between the structural parameters of the investigated derivatives and their antiplatelet aggregation
activity was performed with various molecular descriptors but, analysis of the physicochemical parameters doesn’t
show a significant correlation between the observed activities and general molecular parameters of the
synthesized derivatives. Although, due to the existence of several receptors on the platelets surface which are
responsible for controlling the platelet aggregation, the investigated compounds in the present study may exert
their activities through binding to more than one of these receptors and therefore no straight forward SAR could
be obtained for them.
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Figure 1 Schematic representation of the general hydrazone
structural backbone with antiplatelet activity.
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Cardiovascular diseases are responsible for the largest
number of death and disability worldwide. Platelet adhe-
sion and aggregation are key events in hemostasis and
thrombosis which cause disrupted atherosclerotic pla-
ques that is the initiator of most thrombotic disorders
including heart attacks and strokes [1-3]. Platelets play
the major role in the pathogenesis of thromboembolic
disorders and activation of the platelets by complex bio-
chemical pathways and mediators is the primary step in
this process [4,5]. Endogenous agonists such as arachi-
donic acid (AA), adenosine 5′-diphosphate (ADP) that
acts on purinergic receptors on the platelet-known as
P2Y receptors, thromboxane A2 (TxA2), thrombin, platelet
activating factor (PAF), epinephrine (EPN) and collagen
are among potent agonists that initiate the formation of
stable platelet aggregates [6-8].
Clinical evidence has clearly proven that antiplatelet
aggregation agents are useful for preventing thrombotic
disorders. On the other hand, there are still some serious
limitations to currently use agents which include weak
inhibition of platelet function (aspirin), slow onset of ac-
tion (clopidogrel), variable response to treatment among
patients and high incidence of bleeding events which is
dose dependent in both aspirin and clopidogrel drug
therapy [9]. Considering the current situation, pursuit of
finding novel scaffolds as new antiplatelet aggregation
drugs which are more effective and safer with fewer side
effects is very important [10].
A novel group of heterocyclic acylhydrazone derivatives
with antiplatelet aggregation activity on rabbit platelet-
rich plasma have been reported [11,12]. Furthermore, the
N-acylhydrazone (NAH) moiety, have shown a series of
biological activities such as analgesic, anti-inflammatory
[13-20], protozoa proteases inhibition [21], HIV-1 reverse
transcriptase dimmer destabilization [22], antibiotic
and antifungal activities [23], and cardiovascular ac-
tions [24-28].
Indole ring is another structural moiety which has
been reported to have antiplatelet aggregation activity
[29]. Considering this background, a diverse group of
derivatives have been synthesized in this study by mo-
lecular hybridization between indole and hydrazone
moieties, to find the structure–antiplatelet activity rela-
tionship of the derivatives. The schematic structural
backbone for these compounds which contain both
indole and N-acylhydrazone is depicted in Figure 1.
Chemistry
The synthetic procedure planned to obtain the desired
indole N-acylhydrazone derivatives, is shown in Scheme 1.
The key intermediates were obtained by hydrazinolysis
of 1 and 4 in 96% and 91% yield, respectively, using
hydrazine monohydrate 99% in ethanol. The final indoleN-acylhydrazone derivatives were obtained by condens-
ing the hydrazide intermediates with the proper aro-
matic aldehydes (ArCHO) in water and glacial acetic
acid as the solvent, in good yields.
Material and methods
General
All commercial solvents, chemicals and reagents were
purchased from either Merck or Sigma-Aldrich with the
highest purity and used without further purification.
Proton nuclear magnetic resonance (1H NMR) spectra
were recorded on a Bruker 500 MHz spectrometers
(Bruker, Rheinstetten, Germany) and pick positions are
illustrated in parts per million (δ) in DMSO-d6 solution
and tetramethylsilane (0.05% v/v) as internal standard
and coupling constant values (J) are given in Hertz. Sig-
nal multiplicities are reported by: s (singlet), d (doublet),
t (triplet), q (quadruplet), m (multiplet) and br (broad
signal). For NMR spectral data assignments, the atom
numbering of compounds is depicted in Table 1. Analyt-
ical thin layer chromatography (TLC) was performed
with Merck silica gel plates and visualized with UV ir-
radiation (254 nm) or iodine. Electrospray ionization
mass spectra (ESI-MS) were obtained using Agilent 6410
Triple Quad. LC/MS. Melting points were obtained by
an Electrothermal 9100 apparatus and are uncorrected.
The IR spectra were taken by a Perkin-Elmer 843 spec-
trometer with KBr as diluent. The elemental analysis for
C, H and N was performed by a Costech model 4010 and
the percentage values agreed with the proposed structures
within ±0.4% of the theoretical values. All described prod-
ucts showed 1H NMR spectra according to the assigned
structures. The physicochemical parameters including
Clog P value, surface area, molecular volume, refractiv-
ity and polarizability were calculated by Hyperchem 8.0
software.
General procedure for the preparation of carbohydrazides
(2, 5)
Compounds (1 or 4) (2.86 mmol) was added to a solu-
tion of hydrazine monohydrate 99% (2.14 mL; 2.18 g;
43.6 mmol) in ethanol (0.5 mL) and the reaction mixture
Scheme 1 The synthesis pathway for indoleN-acylhydrazones. Reagents and reaction condition: a) Hydrazine monohydrate 99% (NH2NH2),
Ethanol (a few drop), reflux at 80°C, 3 h b) ArCHO, H2O, Glacial acetic acid (a few drop), reflux at 100°C, 3 h.
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indicated the end of reaction. The mixture was cooled
by addition of a water/ice mixture. The solid was filtered
in excellent yield (Scheme 1) [30-32].
1H- indole-3-carbohydrazide (2) and 1H- indole-2-
carbohydrazide (5) were prepared according to a litera-
ture method [30-32].
General procedure for the preparation of N-acylhydrazone
derivatives
Equimolar amount of appropriate aromatic aldehyde was
added to a solution of hydrazide compound (2 or 5) in
10 mL of water, in presence of catalytic amount of gla-
cial acetic acid (0.4 mL). Reaction mixture was heated
under reflux with stirring for about 2 h and poured into
ice/water mixture. The precipitate was filtered and washed
with cold water (Scheme 1).
N’-(4-hydroxybenzylidene)-1H-indole-3-carbohydrazide
(3i), N’-(3-hydroxybenzylidene)-1H-indole-3-carbohydra-
zide (3j), N’-benzylidene-1H-indole-3-carbohydrazide (3 m),
N’-(2-hydroxybenzylidene)-1H-indole-2-carbohydrazide (6e),
N’-(2-methoxybenzylidene)-1H-indole-2-carbohydrazide (6f)
and N’-benzylidene-1H-indole-2-carbohydrazide (6i) were
prepared according to a literature method [30-32].
N’-(2-hydroxybenzylidene)-1H-indole-3-carbohydrazide (3d)
Yield: 92%, mp 256- 259°C. IR (KBr) cm-1: 3365 (ν OH),
3283, 3041, 2927, 1660, 1614, 1596, 1577, 1564. 1H NMR
(500 MHz, DMSO): δ 11.79 (s, 1H, CONH), 11.71 (bs, 1H,
Indole NH), 11.51 (bs, 1H, OH), 8.52 (s, 1H, ─N═CH─)
8.21 (bs, 1H, ─N═CH─C6H5, H2), 8.20 (d, 1H, J =
7.85 Hz, ─N═CH─C6H5 ,H4), 7.52 (d, 1H, J =
7.5 Hz, ─N═CH─C6H5, H6), 7.50 (d, 1H, J = 7.8
Hz, ─N═CH─C6H5, H4), 7.29 (td, 1H, J = 7.0, 1.40 Hz,
Indole H7), 7.21 (td, 1H, J = 7.4, 1.45 Hz, Indole H5), 7.17
(td, 1H, J = 7.0, 1.45 Hz, Indole H6), 6.95- 6.91 (m,
2H, ─N═CH─C6H5, H3, H5), ESI-Mass m/z: 280 [M+
H]+, 302 [M + Na]+; Anal. Calcd. for C16H13N3O2: C,68.81; H, 4.69; N, 15.05. Found: C, 68.64; H, 4.83; N,
14.92.
N’-(2-nitrobenzylidene)-1H-indole-3-carbohydrazide (3e)
Yield: 96%, mp 272- 274°C. IR (KBr) cm-1: 3282, 3218,
3143, 3089, 1635, 1595, 1564, 1540 and 1353 (NO2).
1H
NMR (500 MHz, DMSO): δ 11.83 (s, 1H, CONH), 11.81
(s, 1H, Indole NH), 8.72 (s, 1H, ─N═CH─C6H5, H2),
8.28 (bs, 1H, ─N═CH─), 8.21 (d, 1H, J = 7.8 Hz, Indole
H4), 8.16 (d, 1H, J = 7.4 Hz, ─N═CH─C6H5, H6), 8.08
(dd, 1H, J = 7.20, 1.0 Hz, ─N═CH─C6H5, H3), 7.83 (t,
1H, J = 7.5 Hz, ─N═CH─C6H5, H5), 7.66 (td, 1H, J = 7.6,
1.35 Hz,─N═CH─C6H5, H4), 7.49 (d, 1H, J = 7.9 Hz, In-
dole H7), 7.23-7.16 (m, 2H, Indole H5, H6), ESI-Mass m/z:
309 [M+H]+, 331 [M+Na]+, 347 [M+K]+; Anal. Calcd.
for C16H12N4O3: C, 62.33; H, 3.92; N, 18.17. Found: C,
62.58; H, 4.08; N, 18.32.
N’-(2-methoxybenzylidene)-1H-indole-3-carbohydrazide (3f)
Yield: 69%, mp 229- 231°C. IR (KBr) cm-1: 3300- 3200
(ν NH), 3112, 3076, 1622, 1601, 1578, 1540; 1H NMR
(500 MHz, DMSO): δ 11.73 (s, 1H, CONH), 11.41 (s,
1H, Indole-NH), 8.65 (bs, 1H, Indole H2 ), 8.22 (bs,
2H, Indole H4, ─N═CH─), 7.87 (d, 1H, J = 6.70
Hz, ─N═CH─C6H5, H6), 7.48 (d, 1H, J = 7. 85 Hz,
Indole H7), 7.41 (td, 1H, J = 7.3, 1.35 Hz,─N═CH─C6H5,
H4), 7.20 (t, 1H, J = 7.0 Hz, ─N═CH─C6H5, H5), 7.15
(t, 1H, J = 7.4 Hz, Indole H5), 7.12 (d, 1H, J = 8.3
Hz, ─N═CH─C6H5, H3), 7.04 (t, 1H, J = 7.4 Hz, In-
dole H6), 3.89 (s, 3H, ─OCH3); ESI-Mass m/z: 294
[M+H]+, 316 [M+Na]+; Anal. Calcd. for C17H15N3O2: C,
69.61; H, 5.15; N, 14.33. Found: C, 69.46; H, 5.33; N,
14.12.
N’-(3-chlorobenzylidene)-1H-indole-3-carbohydrazide (3 g)
Yield: 78%, mp 288- 291°C. IR (KBr) cm-1: 3545, 3390,
3320, 3263, 3068, 1635, 1580, 1558,1548; 1H NMR
(500 MHz, DMSO): δ 11.78 (s, 1H, CONH), 11.50 (s, 1H,
Table 1 Effect of 3-substituted indole (3d-m) and 2-substituted indole (6d-i) derivatives at 1 mM concentration
onin-vitroplatelet aggregation induced by AA, ADP and collagen
Derivative Structure AA ADP Collagen
Inhibition (%)b
3d 30.1 ± 3 31 ± 1.5 24.5 ± 2.1
3e 94 ± 5 20 ± 1.3 80 ± 4.3
3f 97 ± 4.9 41.5 ± 2.1 73.6 ± 2.9
3 g 94 ± 2.5 46 ± 2.5 65.6 ± 3.1
3h 95 ± 3.9 21.3 ± 1 44.6 ± 2.1
3i 97 ± 5.1 47.5 ± 1.2 74 ± 3.9
3j 96 ± 4.6 42.8 ± 0.9 81 ± 1.9
3 k 93 ± 1.9 55 ± 1.3 91 ± 2.7
Mirfazli et al. DARU Journal of Pharmaceutical Sciences 2014, 22:65 Page 4 of 10
http://www.darujps.com/content/22/1/65
Table 1 Effect of 3-substituted indole (3d-m) and 2-substituted indole (6d-i) derivatives at 1 mM concentration
onin-vitroplatelet aggregation induced by AA, ADP and collagen (Continued)
3 l 94 ± 3 53 ± 2.1 91 ± 0.9
3 m 94 ± 2.8 35 ± 1.2 100 ± 2.0
6d 96 ± 4.1 31.4 ± 1.4 61.6 ± 3.2
6e 35 ± 2.5 66.8 ± 1.1 8 ± 0.9
6f 94.5 ± 3.1 25.9 ± 0.6 61 ± 3
6 g 100 ± 3.8 26.8 ± 1 27.3 ± 1.2
6 h 96 ± 2.9 24 ± 0.8 100 ± 3.4
6i 98 ± 1.4 51 ± 1.3 80 ± 2.5
Indomethacina 100 ± 4.3 42 ± 1.1 100 ± 2.8
Aspirina 100 ± 2.8 21 ± 0.6 100 ± 3.1
aAspirin and Indomethacin were used as a positive control.
bValues are presented as mean ± S.E. of three separate determination.
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H2), 8.20 (s, 1H, Indole H4), 7.78 (s, 1H,─N═CH─C6H5,
H2), 7.68 (d, 1H, J = 7.0 Hz, ─N═CH─C6H5, H6), 7.51-
7.47 (m, 3H, Indole H7, ─N═CH─C6H5, H4, H5), 7.22-
7.15 (m, 2H, Indole H5, H6); ESI-Mass m/z: 298 [M+H]
+,
320 [M+Na]+; Anal. Calcd. for C16H12ClN3O: C, 64.54;
H, 4.06; N, 11.91. Found: C, 64.19; H, 4.24; N, 11.76.
N’-(4-chlorobenzylidene)-1H-indole-3-carbohydrazide (3 h)
Yield: 74%, mp 265- 267°C. IR (KBr) cm-1: 3394, 3240,
3060, 1637, 1603, 1555, 1536; 1H NMR (500 MHz,
DMSO): δ 11.76 (s, 1H, CONH), 11.45 (s, 1H, Indole-
NH), 8.35- 8.21 (m, 3H, ─N═CH─, Indole H2, H4),
7.75 (d, 2H, J = 8.5 Hz, ─N═CH─C6H5, H2, H6), 7.53
(d, 2H, J = 8.5 Hz, ─N═CH─C6H5, H3, H5), 7.49 (d,
1H, J = 8.0 Hz, Indole H7), 7.22- 7.15 (m, 2H, Indole H5,
H6); ESI-Mass m/z: 298 [M +H]
+, 320 [M +Na]+; Anal.
Calcd. for C16H12ClN3O: C, 64.54; H, 4.06; N, 11.91.
Found: C, 64.43; H, 3.91; N, 12.16.
N’-(2-fluorobenzylidene)-1H-indole-3-carbohydrazide (3 k)
Yield: 90%, mp 239- 240°C. IR (KBr) cm-1: 3299- 3073 (ν
NH), 3032, 2956, 1636, 1614, 1586, 1555. 1H NMR
(500 MHz, DMSO): δ 11.77 (s, 1H, CONH), 11.50 (bs,
1H, Indole NH), 8.55 (bs, 1H,─N═CH─), 8.22 (d, 1H, J =
7.5 Hz, Indole H4), 7.94 (t, 1H, J = 6.8 Hz,─N═CH─C6H5,
H4), 7.50- 7.45 (m, 3H, ─N═CH─C6H5, H6, Indole H2,
H7), 7.33- 7.29 (m, 2H, ─N═CH─C6H5, H3, H5), 7.21
(td, 1H, J = 6.5, 1.3 Hz, Indole H5), 7.16 (td, 1H, J = 6.5,
1.3 Hz, Indole H6); ESI-Mass m/z: 282 [M+H]
+, 304 [M+
Na]+; Anal. Calcd. for C16H12FN3O: C, 68.32; H, 4.30; N,
14.94. Found: C, 68.64; H, 4.13; N, 14.62.
N’-(3-fluorobenzylidene)-1H-indole-3-carbohydrazide (3 l)
Yield: 87%, mp 278- 281°C. IR (KBr) cm-1: 3319- 3200 (ν
NH), 3139, 3089, 1647, 1591, 1558, 1500. 1H NMR
(500 MHz, DMSO): δ 11.76 (s, 1H, CONH), 11.50 (bs,
1H, Indole NH), 8.34- 8.27 (m, 3H, ─N═CH─, Indole
H4, H2), 7.57- 7.48 (m, 4H, ─N═CH─C6H5 ,H2, H5,
H6, Indole, H7), 7.28- 7.24 (m, 1H, ─N═CH─C6H5,
H4), 7.21 (td, 1H, J = 6.8, 1.2 Hz, Indole H5), 7.16 (td,
1H, J = 6.8, 1.2 Hz, Indole H6); ESI-Mass m/z: 282 [M +
H]+, 304 [M +Na]+; Anal. Calcd. for C16H12FN3O: C,
68.32; H, 4.30; N, 14.94. Found: C, 68.14; H, 4.03; N,
15.02.
N’-(2-fluorobenzylidene)-1H-indole-2-carbohydrazide (6d)
Yield: 98%, mp 186- 188°C. IR (KBr) cm-1: 3450, 3227,
3038, 2922, 1643, 1621, 1612, 1593, and 1564. 1H NMR
(500 MHz, DMSO): δ 12.03 (s, 1H, CONH), 11.85 (s, 1H,
Indole NH), 8.71 (s, 1H, ─N═CH─), 7.98 (t, 1H, J =
7.3 Hz, ─N═CH─C6H5 ,H4), 7.70 (d, 1H, J = 7.8
Hz, ─N═CH─C6H5,H6), 7.52- 7.47 (m, 2H, IndoleH4, H7), 7.35- 7.32 (m, 2H, Indole H5, H6), 7.24 (t,
1H, J = 7.4 Hz, ─N═CH─C6H5, H3), 7.08 (t, 1H, J =
7.4 Hz, ─N═CH─C6H5, H5); ESI-Mass m/z: 282
[M + H]+; Anal. Calcd. for C16H12FN3O: C, 68.32; H,
4.30; N, 14.94. Found: C, 68.14; H, 4.63; N, 15.12.
N’-(3-fluorobenzylidene)-1H-indole-2-carbohydrazide (6 g)
Yield: 88%, mp 171- 173°C. IR (KBr) cm-1: 3448, 3313,
3264, 3126, 3071, 1629, 1597, 1577, 1529; 1H NMR
(500 MHz, DMSO): δ 12.02 (s, 1H, CONH), 11.84 (s,
1H, Indole NH), 8.47 (s, 1H,─N═CH─), 7.70 (d, 1H, J =
8.0 Hz, ─N═CH─C6H5 ,H2),7.61 (d, 1H, J = 7.3 Hz, In-
dole H7), 7.58- 7.52 (m, 2H, ─N═CH─C6H5 H5, Indole,
H4), 7.48 (d, 1H, J = 8.0 Hz,─N═CH─C6H5, H6), 7.34 (s,
1H, Indole H3), 7.30 (t, 1H, J = 8.5 Hz, ─N═CH─C6H5,
H6), 7.24 (t, 1H, J = 7.5 Hz, Indole H6), 7.08 (t, 1H, J =
7.5 Hz, Indole H5); ESI-Mass m/z: 282 [M + H]
+, 304
[M + Na]+; Anal. Calcd. for C16H12FN3O: C, 68.32; H,
4.30; N, 14.94. Found: C, 68.01; H, 4.33; N, 14.62.
N’-(3-hydroxybenzylidene)-1H-indole-2-carbohydrazide (6 h)
Yield: 89%, mp 278- 281°C. IR (KBr) cm-1: 3412 (ν OH),
3227, 3185, 3048, 2924, 1624, 1599, 1583, 1564, 1507; 1H
NMR (500 MHz, DMSO): δ 12.05 (s, 1H, CONH), 11.84
(bs, 2H, Indole NH, OH), 8.44 (s, 1H, ─N═CH─), 7.82
(s, 1H, ─N═CH─C6H5, H2), 7.74- 7.68 (m, 2H, Indole
H4, H7), 7.53- 7.51 (m, 2H, ─N═CH─C6H5, H5, H6),
7.47 (d, 1H, J = 8.3 Hz, ─N═CH─C6H5, H4), 7.34 (s,
1H, Indole H3), 7.24 (t, 1H, J = 7.1 Hz, Indole H6), 7.08
(t, 1H, J = 7.1 Hz, Indole H5); ESI-Mass m/z: 280 [M +
H]+, 302 [M +Na]+; Anal. Calcd. for C16H13N3O2: C,
68.81; H, 4.69; N, 15.05. Found: C, 69.04; H, 4.41; N,
14.92.
Biological assay
In vitro evaluation of anti-platelet aggregation activity
Human plasma used to measure the derivatives anti-
platelet aggregation activity. Fresh blood was obtained
from healthy volunteer with negative history of drug
consumption from 15 days prior to the test. Platelet-
rich plasma (PRP) was obtained from citrated whole
blood (9:1 by volume) which centrifuged at 1,000 rpm
for 8 min. The remained layer was centrifuged at
3,000 rpm for 15 min and the upper layer; PPP (Platelet
poor plasma) was collected as the blank. The platelet
count was adjusted to 250,000 plts/mL by diluting PRP
with appropriate amount of PPP. To the PRP samples, test
compounds previously dissolved in DMSO (at 0.05% final
concentration) were added and samples were incubated
for 5 min at 37°C. Then ADP (5 μM), collagen (1.25 mg/mL)
or AA (1.25 mg/mL) was added and platelet shape change
and aggregation were monitored for 5 min. DMSO (0.5% v/v)
was used as negative control and aspirin and indomethacin
Table 2 General molecular parameters of the synthesized
compounds
Compound Clog P Ra Pb Vc SAd
Approx. Grid
3d 2.92 86.69 30.1 771.23 374.67 469.41
3e -0.15 92.78 32.03 809.38 404.94 487.59
3f 3.35 88.16 30.83 781.07 373.02 472.72
3g 2.72 90.56 31.99 854.73 356.93 517.77
3h 3.85 91.28 32.12 807.06 402.79 488.39
3i 3.28 86.69 30.1 772.67 378.22 470.61
3j 2.72 88.16 30.83 784.59 381.64 474.45
3k 2.72 88.16 30.83 783.92 379.99 474.45
3l 3.85 91.28 32.12 807.9 403.8 488.87
3m 3.14 86.56 30.19 764.21 367.69 464.55
6d 3.26 87.96 30.1 775.75 381.25 476.6
6e 3.69 89.44 30.83 787.22 379.72 479.81
6f 3.06 94.21 32.66 844.8 422.2 515.34
6g 3.62 87.96 30.1 778.08 384.8 477.59
6h 3.06 89.44 30.83 791.05 387 482.43
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aggregation was calculated by the following formula:
Inhibition% ¼ 1‐ D=Sð Þ½   100
D = platelet aggregation in the presence of test com-
poundsS = platelet aggregation in the presence of solvent.
The platelet aggregation inhibitory activity was expressed
as percent inhibition by comparison with that measured
for the vehicle (DMSO) alone and IC50 values were ob-
tained from log (concentration) − inhibition (%) diagram
and was defined as the concentration of the test com-
pound that inhibits the platelet aggregation by 50%. Data
were presented as mean ± S.E.M. of three independent
experiments performed in triplicate. IC50values and inhib-
ition data were analyzed with prism software.
Consent
The study was approved in the Institute Review Board
with code number 93-6-10:1–1. Written informed consent
was obtained from the patient for the publication of this
report and any accompanying images.
Results
The synthetic pathway is disclosed in Scheme 1. Final
desired derivatives were prepared by a two-step proced-
ure. The structures were confirmed by spectroscopic
techniques including IR, Mass and 1H NMR. Molecular
mass of all the derivatives was determined by Electron-
spray ionization mass spectrometry (ESI–MS) as M + 1
and/or M + 23 relating to hydrogen and sodium adducts
of the intact molecules, respectively. All the synthesized
compounds were evaluated for their ability to inhibit
platelet aggregation of human platelet-rich plasma (PRP)
induced by AA, ADP and collagen as potent aggregation
inducers, and using indomethacin and aspirin were ap-
plied as standard drugs. The results of in-vitro antiplatelet
aggregation activity for the title compounds were summa-
rized in Table 1. All the derivatives were initially tested at
1 mM.
The physicochemical parameters of the derivatives were
calculated and are listed in Table 2.
Discussion
Chemistry
All derivatives of 3-substituted indole and 2-substituted
indole were obtained by the reaction of 2 and 5 with the
proper aldehydes. Synthesis of Schiff bases were per-
formed in ethanol with a few drops of glacial acetic acid.
This reaction in the majority of the cases was straight
forward; however, the products were soluble in ethanol
and their separation was difficult. Therefore in another
effort, the solvent was changed to water, a few drops of
glacial acetic acid was added to the reaction mixture andheated for 10 min. After completion of reaction, the
products were obtained in excellent yields.
In the 1H NMR spectra of these compounds the exist-
ence of two singlet at 11.00 to 12.00 ppm was assigned
to hydrazide NH and indole NH. Also, singlet signal at
8.20-8.80 ppm was assigned to H─C =N. The 1H NMR
and ESI-mass data of compounds approved the exact
structures.
Antiplatelet aggregation activity
Platelet activation and thrombus formation are major
causes of cardiovascular diseases and thrombosis.
Thus, antiplatelet therapy is a useful way to prevent or
treat these diseases; these diseases; thus, antiplatelet
agents such as aspirin, ticlopidine and dipyridamole have
been clinically used for thrombus-related diseases [9].
However, the side effects of mentioned agents frequently
have been reported and a new group of compounds with
greater efficacy and safety are desired. Therefore, in the
present study, the inhibitory effects of synthesized com-
pounds on platelet aggregation were evaluated by turbidi-
metric method reported by Born and Cross [33] using
APACT 4004 aggregometer. The baseline value was set
using PRP and maximal transmission using PPP. Com-
pounds 3d-m and 6d-i were tested for anti-platelet aggre-
gation activity induced by adenosine diphosphate (ADP),
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and aspirin as standards.
Interestingly, most of the tested derivatives selectively
inhibited platelet aggregation induced by AA and collagen
with satisfactory percent inhibition values. According to
the literature [15]; herein, antiplatelet aggregation activity
of N-acylhydrazones is probably related to modulation of
AA cascade enzymes.
Among the synthesized indole-2-carbaldehyde deriva-
tives compound 6g exhibited 100% inhibition of platelet
aggregation at 1 mM when AA was used as agonist while
this compound has no significant inhibitory activity against
ADP and collagen induced platelet aggregation. Comparing
the results obtained for indole derivatives, compounds 3m
and 6h showed the best antiplatelet aggregation effect
which induced by collagen. On the other hand, effects of
the synthesized compounds on the platelet aggregation in-
duced by ADP shows another pattern: all the compounds
caused no significant inhibition on platelet aggregation ex-
cept 6e which showed 66.7% inhibition.
The IC50 values were calculated for more potent com-
pounds (3f, 3i, 3k, 3l, 3m, 6d, 6g, 6h and 6i) for the
inhibition of AA and collagen-induced aggregation which
are shown in Table 3.
However, the obtained results were compared with
those reported by Kobarfard et al. on antiplatelet aggre-
gation effect of some indole derivatives [4]. It was found
that the insertion of acyl group to indole hydrazone moi-
ety cannot improve platelet aggregation inhibitory activity.
In order to investigate the possible relationship between
the structural parameters of the investigated derivatives
and their antiplatelet aggregation activity, quantitative
structure–activity relationship (QSAR) analysis was per-
formed with various molecular descriptors. The calculatedTable 3 IC50values for the antiplatelet aggregation





3f 2-methoxyphenyl 310±8.1 121.5±3.1
3i 4-hydroxyphenyl 290±5.3 188±2.8
3k 2-fluorophenyl 179±2.4 122±1.6
3l 3-fluorophenyl 321±3.9 120±4.0
3m phenyl 182±5.2 21±0.9
6d 2-fluorophenyl 286±1.5 720±9.1
6g 3-fuorophenyl 140±4.3 >1000
6h 3-hydroxyphenyl 200±2.0 190±3.2
6i phenyl 94±1.9 134±4.1
Indomethacin 3±0.2 1.2±0.1
Aspirin 30.3±2.6 9.7±0.6
aData related to compounds 3 and 6 as shown in Scheme 1.
bIC50 values represent mean ± S.E. of triplicate measurements from one of
three independent experiments.octanol–water partition coefficient (Clog P) has been con-
sidered as descriptor for the hydrophobic effect. The steric
effect has been described by means of the surface area
(SA: approx and grid) and molecular volume (V) refractiv-
ity (R) and polarizability (P) have been used as descriptors
for both volume and electronic state (London dispersive
forces) properties of the molecules. For each descriptor,
the best multilinear regression equation was obtained.
The calculated physicochemical parameters of the deriva-
tives are listed in Table 2. Analysis of the physicochemical
parameters doesn’t show a significant correlation between
the observed activities and general molecular parameters
of the synthesized derivatives.
Conclusion
In summary, we have synthesized sixteen N-acylhydrazone
derivatives (3d-m and 6d-i) and evaluated their antiplate-
let aggregation activity against collagen, ADP and AA as
the aggregation inducers. Compounds 3e, 3g, 3h, 3i, 3j,
3k, 3l, 3m, 6d, 6f, 6g, 6h and 6i showed significant anti-
platelet aggregation (>90%) when arachidonic acid was
used as the inducer. While, 3l, 3k, 3m and 6h exhibited
best (>90%) platelet aggregation inhibition induced by
collagen among other compounds.
Failure to extract a clear correlation between activities
and general molecular parameters of the synthesized com-
pounds could be related to the existence of several recep-
tors on the platelets surface which are responsible for
controlling platelet aggregation. Platelets are activated by
variety of metabolic pathways. The mechanism of platelet
aggregation pathway is very complex and involves mul-
tiple components and it can be controlled by heteroge-
neous group of endogenous compounds such as ADP,
ATP, collagen, tryptophan, epinephrine, thromboxane A2
and calcium. Each can independently and together begin
the process leading to platelet aggregation. These com-
pounds on platelets have specific receptors and the inves-
tigated compounds in the present study may exert their
activities through binding to more than one of these
receptors and therefore no straight forward SAR could be
obtained. The findings of this study will be helpful for the
development of new antiplatelet compounds providing
some directions in the area of antiplatelet drug discovery.
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